Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2

Highlights • Lung cancer with PS2 status is a common condition accounting around 40%. • Economic data is useful to complement data about safety and efficacy. • This is the first economic analysis based on PS2 dedicated trial of NSCLC patients. • Carboplatin plus pemetrexed is cost-effective when com...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-09, Vol.89 (3), p.274-279
Main Authors: Schluckebier, Luciene, Garay, Osvaldo U, Zukin, Mauro, Ferreira, Carlos G
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Cost effectiveness
Cost-Benefit Analysis
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Neoplasm Staging
Non-small cell lung cancer
Pemetrexed
Pemetrexed - administration & dosage
Pemetrexed - therapeutic use
PS2 patients
Pulmonary/Respiratory
Quality-Adjusted Life Years
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Lung cancer with PS2 status is a common condition accounting around 40%. • Economic data is useful to complement data about safety and efficacy. • This is the first economic analysis based on PS2 dedicated trial of NSCLC patients. • Carboplatin plus pemetrexed is cost-effective when compared with pemetrexed. • Dedicated PS2 clinical trials and economic evaluations should be encouraged.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2015.06.015